A Phase 2 interventional study of nemolizumab (CIM331) and Placebo in Atopic Dermatitis, sponsored by Chugai Pharmaceutical. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-25.
Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Galderma R&D · Sites in United States
Ages 6 mo–23 mo
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 264 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 209 across the 14 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Chugai Pharmaceutical, one of the names counted as Hoffmann-La Roche. Under that name alone:
Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Hoffmann-La Roche has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
1 of the studies testing nemolizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07762833Phase 3Galderma R&DRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
Drug: nemolizumab (CIM331)
Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
Drug: nemolizumab (CIM331)
Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
Drug: nemolizumab (CIM331)
Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
Drug: nemolizumab (CIM331)
Part A: Placebo Part B: nemolizumab (CIM331)
Drug: nemolizumab (CIM331) · Other: Placebo
Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12
Percent changes from baseline in pruritus VAS at Week 12. VAS indicates pruritus intensity in the last 24 hours, from 0 (no itch) to 10 (worst imaginable itch). When condition of pruritus improves, percent change from baseline at Week 12 indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population)
EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12 (Part A)
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population)
EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population)
SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12 (Part A)
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population)
SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population)
The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12 (Part A)
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population)
The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population)
The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).
Time frame: baseline to Week 12 (Part A)
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population)
The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).
Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)
The patients were enrolled at 57 investigational sites in the UK, Germany, Poland, Japan, and the US.
| Milestone | Placebo | Nemoliozumab (0.1 mg/kg) Q4W | Nemoliozumab (0.5 mg/kg) Q4W | Nemoliozumab (2.0 mg/kg) Q4W | Nemoliozumab (2.0 mg/kg) Q8W |
|---|---|---|---|---|---|
| Started | 53 | 53 | 54 | 52 | 52 |
| Completed | 44 | 44 | 45 | 45 | 38 |
| Not completed | 9 | 9 | 9 | 7 | 14 |
| Withdrew: Adverse event | 1 | 5 | 2 | 2 | 4 |
| Withdrew: Lack of efficacy | 3 | 1 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 5 | 2 | 6 | 2 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Others (not classified above reasons) | 0 | 0 | 0 | 0 | 2 |
| Milestone | Placebo | Nemoliozumab (0.1 mg/kg) Q4W | Nemoliozumab (0.5 mg/kg) Q4W | Nemoliozumab (2.0 mg/kg) Q4W | Nemoliozumab (2.0 mg/kg) Q8W |
|---|---|---|---|---|---|
| Started | 0 | 41 | 38 | 39 | 35 |
| Completed | 0 | 31 | 28 | 30 | 19 |
| Not completed | 0 | 10 | 10 | 9 | 16 |
| Withdrew: Adverse event | 0 | 2 | 0 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 3 | 2 | 0 | 4 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 7 | 6 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Others (not classified above reasons) | 0 | 1 | 0 | 1 | 1 |
| Milestone | Placebo | Nemoliozumab (0.1 mg/kg) Q4W | Nemoliozumab (0.5 mg/kg) Q4W | Nemoliozumab (2.0 mg/kg) Q4W | Nemoliozumab (2.0 mg/kg) Q8W |
|---|---|---|---|---|---|
| Started | 0 | 13 | 12 | 13 | 0 |
| Completed | 0 | 8 | 7 | 8 | 0 |
| Not completed | 0 | 5 | 5 | 5 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
Percent changes from baseline in pruritus VAS at Week 12. VAS indicates pruritus intensity in the last 24 hours, from 0 (no itch) to 10 (worst imaginable itch). When condition of pruritus improves, percent change from baseline at Week 12 indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| percentage change | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) |
|---|---|---|---|---|
| Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 | -20.07 (-29.94 to -10.21) | -41.46 (-51.21 to -31.71) | -61.24 (-71.13 to -51.35) | -60.46 (-69.98 to -50.95) |
EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| percentage change from baseline | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) |
|---|---|---|---|---|
| Week 4 | -12.12 ± 40.00 | -26.89 ± 44.48 | -35.70 ± 44.29 | -33.86 ± 34.14 |
| Week 8 | -21.82 ± 47.00 | -25.17 ± 51.79 | -46.20 ± 42.62 | -39.89 ± 34.43 |
| Week 12 | -20.89 ± 47.63 | -27.88 ± 50.50 | -44.57 ± 48.21 | -40.29 ± 37.70 |
EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| percentage change from baseline | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) |
|---|---|---|---|---|
| Week 4 | -25.47 ± 42.41 | -32.11 ± 43.70 | -32.48 ± 34.02 | -25.43 ± 35.58 |
| Week 8 | -25.13 ± 49.82 | -47.86 ± 41.38 | -41.02 ± 36.50 | -33.35 ± 38.00 |
| Week 12 | -35.11 ± 47.92 | -47.75 ± 45.41 | -46.78 ± 35.15 | -42.12 ± 40.82 |
| Week 24 | -55.83 ± 42.25 | -62.71 ± 44.37 | -56.26 ± 34.68 | -51.01 ± 37.07 |
| Week 48 | -69.90 ± 28.17 | -71.16 ± 43.31 | -61.14 ± 44.43 | -74.29 ± 33.97 |
| Week 60 | -63.11 ± 41.89 | -78.81 ± 28.82 | -70.85 ± 36.24 | -70.87 ± 32.84 |
| Week 64 | -68.45 ± 41.62 | -75.79 ± 25.40 | -78.91 ± 24.34 | -69.25 ± 43.96 |
SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| percentage change from baseline | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) |
|---|---|---|---|---|
| Week 4 | -6.83 ± 25.97 | -29.31 ± 23.58 | -34.59 ± 29.36 | -29.82 ± 21.65 |
| Week 8 | -17.29 ± 30.74 | -26.41 ± 26.60 | -36.81 ± 29.04 | -34.72 ± 24.33 |
| Week 12 | -15.97 ± 26.99 | -27.22 ± 25.81 | -39.49 ± 32.68 | -38.31 ± 28.85 |
SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| percentage change from baseline | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) |
|---|---|---|---|---|
| Week 4 | -27.73 ± 23.92 | -30.30 ± 30.39 | -28.20 ± 22.65 | -25.31 ± 22.68 |
| Week 8 | -29.05 ± 27.17 | -36.16 ± 28.60 | -37.52 ± 23.34 | -31.81 ± 28.42 |
| Week 12 | -36.35 ± 22.24 | -42.22 ± 30.72 | -42.60 ± 27.12 | -41.85 ± 20.79 |
| Week 24 | -48.73 ± 27.64 | -58.15 ± 28.15 | -52.00 ± 24.97 | -49.97 ± 24.99 |
| Week 48 | -55.82 ± 24.21 | -59.20 ± 28.61 | -53.82 ± 29.98 | -66.15 ± 24.43 |
| Week 60 | -55.08 ± 24.22 | -64.02 ± 24.24 | -63.26 ± 25.04 | -61.03 ± 24.27 |
| Week 64 | -56.55 ± 28.25 | -64.02 ± 27.72 | -66.61 ± 19.90 | -63.07 ± 27.96 |
The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| change from baseline | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) |
|---|---|---|---|---|
| Week 4 | -0.2 ± 0.8 | -0.8 ± 0.9 | -0.9 ± 0.9 | -0.6 ± 0.9 |
| Week 8 | -0.5 ± 1.2 | -0.7 ± 1.0 | -1.0 ± 1.2 | -0.8 ± 1.0 |
| Week 12 | -0.3 ± 1.0 | -0.7 ± 1.0 | -1.0 ± 1.1 | -0.8 ± 1.1 |
The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).
| change from baseline | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) |
|---|---|---|---|---|
| Week 4 | -0.7 ± 0.9 | -0.8 ± 0.9 | -0.6 ± 0.9 | -0.4 ± 0.8 |
| Week 8 | -0.8 ± 1.0 | -1.0 ± 1.2 | -0.9 ± 0.9 | -0.5 ± 0.9 |
| Week 12 | -0.9 ± 0.9 | -1.1 ± 1.1 | -0.9 ± 1.0 | -0.9 ± 0.8 |
| Week 24 | -1.5 ± 1.1 | -1.7 ± 1.0 | -1.2 ± 1.0 | -1.2 ± 1.1 |
| Week 48 | -1.7 ± 1.2 | -1.8 ± 0.8 | -1.4 ± 1.2 | -2.0 ± 1.2 |
| Week 60 | -1.9 ± 1.0 | -2.0 ± 0.9 | -1.7 ± 1.1 | -1.7 ± 1.1 |
| Week 64 | -1.9 ± 1.1 | -1.9 ± 0.9 | -1.7 ± 1.0 | -1.8 ± 1.3 |
The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).
| percentage change from baseline | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) |
|---|---|---|---|---|
| Week 4 | -7.48 ± 37.14 | -12.11 ± 43.69 | -23.49 ± 40.93 | -18.44 ± 35.47 |
| Week 8 | -14.44 ± 49.29 | -14.90 ± 45.84 | -27.23 ± 47.17 | -22.99 ± 38.58 |
| Week 12 | -13.29 ± 49.87 | -17.54 ± 47.16 | -19.68 ± 67.49 | -24.36 ± 41.84 |
The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).
| percentage change from baseline | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) |
|---|---|---|---|---|
| Week 4 | -10.12 ± 45.56 | -23.28 ± 38.96 | -17.98 ± 35.12 | -2.79 ± 54.12 |
| Week 8 | -18.08 ± 45.82 | -29.58 ± 47.13 | -24.64 ± 37.49 | -6.66 ± 59.40 |
| Week 12 | -24.53 ± 49.77 | -25.31 ± 63.43 | -25.91 ± 44.40 | -18.56 ± 52.30 |
| Week 24 | -48.13 ± 39.07 | -51.41 ± 44.10 | -40.53 ± 42.94 | -36.91 ± 40.99 |
| Week 48 | -65.21 ± 32.63 | -69.20 ± 39.95 | -49.66 ± 44.18 | -59.97 ± 50.32 |
| Week 60 | -60.41 ± 37.00 | -70.44 ± 35.81 | -60.99 ± 48.00 | -58.38 ± 44.97 |
| Week 64 | -62.54 ± 40.92 | -66.01 ± 36.38 | -63.35 ± 40.37 | -60.54 ± 55.96 |
Collected over baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Part A) | 0/53 (0%) | 1/53 (1.9%) | 27/53 (50.9%) |
| Nemoliozumab (0.1 mg/kg) Q4W (Part A) | 0/53 (0%) | 1/53 (1.9%) | 29/53 (54.7%) |
| Nemoliozumab (0.5 mg/kg) Q4W (Part A) | 0/54 (0%) | 0/54 (0%) | 23/54 (42.6%) |
| Nemoliozumab (2.0 mg/kg) Q4W (Part A) | 0/52 (0%) | 3/52 (5.8%) | 27/52 (51.9%) |
| Nemoliozumab (2.0 mg/kg) Q8W (Part A) | 0/52 (0%) | 5/52 (9.6%) | 25/52 (48.1%) |
| Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | 0/53 (0%) | 3/53 (5.7%) | 37/53 (69.8%) |
| Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | 0/54 (0%) | 3/54 (5.6%) | 35/54 (64.8%) |
| Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | 0/52 (0%) | 4/52 (7.7%) | 33/52 (63.5%) |
| Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) | 0/52 (0%) | 9/52 (17.3%) | 35/52 (67.3%) |
| Event | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/53 | 0/53 | 0/54 | 2/52 | 1/52 | 0/53 | 1/54 | 2/52 | 2/52 |
| InfectionInfections and infestations | 0/53 | 0/53 | 0/54 | 0/52 | 2/52 | 0/53 | 0/54 | 0/52 | 2/52 |
| Dermatitis exfoliativeSkin and subcutaneous tissue disorders | 0/53 | 0/53 | 0/54 | 0/52 | 1/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| Herpes simplexInfections and infestations | 0/53 | 0/53 | 0/54 | 0/52 | 1/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| Herpes zosterInfections and infestations | 0/53 | 0/53 | 0/54 | 0/52 | 1/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| PyelonephritisInfections and infestations | 0/53 | 0/53 | 0/54 | 0/52 | 0/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| Skin infectionInfections and infestations | 0/53 | 0/53 | 0/54 | 1/52 | 0/52 | 0/53 | 0/54 | 1/52 | 0/52 |
| Coronary artery stenosisCardiac disorders | 0/53 | 0/53 | 0/54 | 0/52 | 0/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| Grand mal convulsionNervous system disorders | 0/53 | 0/53 | 0/54 | 0/52 | 0/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| Parkinson's diseaseNervous system disorders | 0/53 | 0/53 | 0/54 | 0/52 | 1/52 | 0/53 | 0/54 | 0/52 | 1/52 |
| Event | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B) | Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B) |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/53 | 9/53 | 6/54 | 5/52 | 7/52 | 15/53 | 14/54 | 15/52 | 12/52 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 7/53 | 11/53 | 10/54 | 9/52 | 9/52 | 15/53 | 12/54 | 12/52 | 9/52 |
| Blood creatine phosphokinase increasedInvestigations | 3/53 | 2/53 | 2/54 | 4/52 | 3/52 | 5/53 | 3/54 | 9/52 | 6/52 |
| Oedema peripheralGeneral disorders | 0/53 | 2/53 | 3/54 | 5/52 | 2/52 | 2/53 | 3/54 | 6/52 | 2/52 |
| Upper respiratory tract infectionInfections and infestations | 6/53 | 4/53 | 1/54 | 4/52 | 5/52 | 6/53 | 3/54 | 5/52 | 5/52 |
| ImpetigoInfections and infestations | 0/53 | 4/53 | 0/54 | 0/52 | 0/52 | 6/53 | 3/54 | 0/52 | 3/52 |
| HeadacheNervous system disorders | 0/53 | 3/53 | 2/54 | 3/52 | 1/52 | 3/53 | 6/54 | 5/52 | 2/52 |
| InfluenzaInfections and infestations | 0/53 | 0/53 | 0/54 | 0/52 | 0/52 | 5/53 | 1/54 | 2/52 | 0/52 |
| PharyngitisInfections and infestations | 0/53 | 0/53 | 0/54 | 0/52 | 0/52 | 1/53 | 3/54 | 3/52 | 1/52 |
| FolliculitisInfections and infestations | 3/53 | 0/53 | 0/54 | 0/52 | 1/52 | 1/53 | 0/54 | 1/52 | 3/52 |
The per-protocol (PP) population in Part A was used for the analysis. The PP population was defined as a subset of the intent to treat (ITT) population excluding some of the major protocol violators, patients who were withdrawn before being evaluated for pruritus Visual Analogue Scale (VAS) at Week 8, or those who withdrew prior to receiving two or more study drug administrations. Patients who received the wrong study drug were also excluded from the PP population.
| Age, Continuous(years) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| Mean | 35.7 ± 13.3 | 33.9 ± 10.2 | 33.0 ± 11.5 | 33.7 ± 12.2 | 34.6 ± 13.3 | 34.2 ± 12.1 |
| Age, Customized(Participants) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| Age Category — < 20 years | 4 | 0 | 3 | 1 | 1 | 9 |
| Age Category — 20 -< 30 years | 14 | 21 | 22 | 20 | 21 | 98 |
| Age Category — 30 -< 40 years | 10 | 15 | 7 | 13 | 7 | 52 |
| Age Category — 40 -< 50 years | 8 | 4 | 6 | 7 | 7 | 32 |
| Age Category — 50 -< 60 years | 8 | 6 | 7 | 4 | 7 | 32 |
| Age Category — > 60 years | 2 | 0 | 0 | 2 | 2 | 6 |
| Sex: Female, Male(Participants) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| Female | 23 | 21 | 27 | 18 | 21 | 110 |
| Male | 23 | 25 | 18 | 29 | 24 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 1 | 3 |
| Not Hispanic or Latino | 45 | 45 | 44 | 45 | 44 | 223 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 13 | 17 | 11 | 15 | 14 | 70 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 6 | 1 | 4 | 15 |
| White | 32 | 26 | 27 | 30 | 27 | 142 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 |
| Height(Centimetre) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| Mean | 167.81 ± 8.84 | 170.19 ± 10.52 | 167.41 ± 9.44 | 170.04 ± 8.84 | 167.58 ± 9.63 | 168.62 ± 9.47 |
| Weight(Kilogram) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| Mean | 74.20 ± 21.60 | 76.01 ± 22.90 | 73.40 ± 19.98 | 72.51 ± 16.04 | 72.63 ± 20.96 | 73.75 ± 20.27 |
| Weight Category(Participants) | Placebo (Part A) | Nemoliozumab (0.1 mg/kg) Q4W (Part A) | Nemoliozumab (0.5 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q4W (Part A) | Nemoliozumab (2.0 mg/kg) Q8W (Part A) | Total |
|---|---|---|---|---|---|---|
| < 60 kg | 11 | 12 | 15 | 11 | 15 | 64 |
| >- 60 kg | 35 | 34 | 30 | 36 | 30 | 165 |
2 further baseline measures are reported on the registry.
The record gives a start of Nov 2013, a primary completion of Apr 2015 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2021, 6 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab